Ticagrelor in the Treatment of Acute Coronary Syndrome: Health Technology Assessment
Shujie Dong,Xiao Liu,Zaiwei Song,Suodi Zhai
DOI: https://doi.org/10.19960/j.cnki.issn1005-0698.2017.07.001
2017-01-01
Abstract:Objective:To support clinical practice and decision-making by evaluating the efficacy,safety and economic efficiency of new platelet inhibition regimens targeting P2Y12-receptors ticagrelor in patients with acute coronary syndrome (ACS).Methods:Database such as PubMed,Embase,the Cochrane Library,Web of Science,CNKI and SinoMed weresearched to collect HTA reports,systematic reviews/meta-analyses,RCTs and pharmacoeconomic studies.Results:In regard to efficacy outcomes,compared with clopidogrel,ticagrelor reduced the incidence of major adverse cardiovascular events (RR =0.86,95 ％ CI:0.79-0.94,P =0.000 4),cardiovascular deaths (RR =0.77,95 ％ CI:0.68-0.88,P ＜ 0.000 1),all-cause mortality (RR =0.81,95 ％ CI:0.71-0.91,P =0.000 8),myocardial infarction (RR =0.82,95 ％ CI:0.73-0.91,P =0.000 2),stent thrombosis (RR =0.74,95％ CI:0.61-0.91,P =0.004).In regard to safety outcomes,ticagrelor didn't increase the incidence of major bleeding (RR =1.04,95 ％ CI:0.96-1.13,P =0.30) and bradycardia (RR =1.12,95 ％ CI:0.98-1.28,P =0.08),while it increased the incidence of major/minor bleeding (RR =1.28,95 ％ CI:1.04-1.58,P =0.02) and dyspnea (RR =1.76,95 ％ CI:1.62-1.91,P ＜ 0.000 01).In regard to economic efficiency,ticagrelor was cost-effectiveness compared to clopidogrel and genotypo-driven antiplatelet therapy.Conclusion:Ticagrelor had favorable profiles in efficacy,safety and economical efficiency in the treatment of ACS.